Biologics Blossoming: CANbridge Looks To Taiwan, WuXi Partners Juno
This article was originally published in PharmAsia News
New policies including the allowance of contract manufacturing under a new marketing holder system are fast changing the nascent biologics sector in China, where the just 2% market penetration for such products is offering plenty of room for a new crop of startups including CANbridge to grow and thrive.
You may also be interested in...
Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.
Celsion plans to bring its first-line immune-oncology drug into clinical studies in China in 2018, with the help from its long-term local partner Zhejiang Hisun Pharmaceuticals. The partnership with Hisun serves multiple strategic purposes for lower costs and quicker approvals in the country where immunotherapeutics is becoming hot new category of cancer treatment.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.